{"generic":"Tegaserod Maleate","drugs":["Tegaserod Maleate","Zelnorm"],"mono":{"0":{"id":"926982-s-0","title":"Generic Names","mono":"Tegaserod Maleate"},"1":{"id":"926982-s-1","title":"Dosing and Indications","sub":{"0":{"id":"926982-s-1-4","title":"Adult Dosing","mono":"<ul><li>Tegaserod maleate was withdrawn from the market on March 30, 2007, following results of a safety analysis that found a higher risk of heart attack, stroke, and worsening heart chest pain in patients treated with tegaserod compared to placebo-treated patients. Clinicians prescribing tegaserod are advised to transition their patients to other therapies as clinically appropriate.<\/li><li>Effective April 2, 2008, tegaserod maleate will no longer be available under the treatment investigational new drug (IND) protocol to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in women younger than 55 years of age, except for use in emergency situations, defined as one that is immediately life-threatening or serious enough to qualify for hospitalization. Request for tegaserod maleate can be made to the U.S. Food and Drug Administration (FDA, druginfo@fda.hhs.gov) which in turn authorizes drug shipment by the manufacturer; however, the FDA reserves the right to deny authorization even in emergency situations based on risks and benefits of individual cases. Potential causes for denial of authorization include prior history of heart attack or stroke, unstable angina, hypertension, hyperlipidemia, diabetes, age above 55 years, smoking, obesity, depression, anxiety and suicidal ideation.<\/li><li><b>Idiopathic constipation, chronic:<\/b> (younger than 65 years of age only) 6 mg ORALLY twice daily before meals; periodically assess need to continue treatment<\/li><li><b>Irritable bowel syndrome:<\/b> (females only) 6 mg ORALLY twice daily before meals for 4 to 6 wks; in patients responding to tegaserod, therapy may be extended for an additional 4 to 6 wks<\/li><\/ul>"},"1":{"id":"926982-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Tegaserod maleate was withdrawn from the market on March 30, 2007, following results of a safety analysis that found a higher risk of heart attack, stroke, and worsening heart chest pain in patients treated with tegaserod compared to placebo-treated patients. Clinicians prescribing tegaserod are advised to transition their patients to other therapies as clinically appropriate.<\/li><li>Effective April 2, 2008, tegaserod maleate will no longer be available under the treatment investigational new drug (IND) protocol to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in women younger than 55 years of age, except for use in emergency situations, defined as one that is immediately life-threatening or serious enough to qualify for hospitalization. Request for tegaserod maleate can be made to the U.S. Food and Drug Administration (FDA, druginfo@fda.hhs.gov) which in turn authorizes drug shipment by the manufacturer; however, the FDA reserves the right to deny authorization even in emergency situations based on risks and benefits of individual cases. Potential causes for denial of authorization include prior history of heart attack or stroke, unstable angina, hypertension, hyperlipidemia, diabetes, age above 55 years, smoking, obesity, depression, anxiety and suicidal ideation.<\/li><li>safety and efficacy have not been established in  pediatric patients<\/li><\/ul>"},"3":{"id":"926982-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Tegaserod maleate was withdrawn from the market on March 30, 2007, following results of a safety analysis that found a higher risk of heart attack, stroke, and worsening heart chest pain in patients treated with tegaserod compared to placebo-treated patients. Clinicians prescribing tegaserod are advised to transition their patients to other therapies as clinically appropriate [1].<\/li><li>Effective April 2, 2008, tegaserod maleate will no longer be available under the treatment investigational new drug (IND) protocol to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in women younger than 55 years of age, except for use in emergency situations, defined as one that is immediately life-threatening or serious enough to qualify for hospitalization. Request for tegaserod maleate can be made to the U.S. Food and Drug Administration (FDA, druginfo@fda.hhs.gov) which in turn authorizes drug shipment by the manufacturer; however, the FDA reserves the right to deny authorization even in emergency situations based on risks and benefits of individual cases. Potential causes for denial of authorization include prior history of heart attack or stroke, unstable angina, hypertension, hyperlipidemia, diabetes, age above 55 years, smoking, obesity, depression, anxiety and suicidal ideation [2].<\/li><li>Idiopathic constipation, chronic<\/li><li>Irritable bowel syndrome<\/li><\/ul>"}}},"3":{"id":"926982-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926982-s-3-9","title":"Contraindications","mono":"<ul><li>abdominal adhesions, history of<\/li><li>bowel obstruction, history of<\/li><li>gallbladder disease, symptomatic<\/li><li>hepatic impairment, moderate or severe<\/li><li>hypersensitivity to tegaserod and any component of the product<\/li><li>renal impairment, severe<\/li><li>sphincter of Oddi dysfunction, suspected history of<\/li><\/ul>"},{"id":"926982-s-3-10","title":"Precautions","mono":"<ul><li>abdominal pain, new or sudden worsening<\/li><li>diarrhea, current or history of frequent episodes; risk of escalating to severe diarrhea<\/li><li>diarrhea, severe, especially accompanied by hypovolemia, hypotension, and syncope<\/li><li>elderly; higher incidence of diarrhea<\/li><li>hypotension; complications have required hospitalizations<\/li><li>ischemic colitis or other intestinal ischemia including rectal bleeding, bloody diarrhea, or new or worsening abdominal pain<\/li><li>syncope; complications have required hospitalizations <\/li><li>prior history of heart attack or stroke, unstable angina, hypertension, hyperlipidemia, diabetes, age above 55 years, smoking, obesity, depression, anxiety, and suicidal ideation; reasons the US Food and Drug Administration may deny authorization for product procurement, even for emergency situations<\/li><\/ul>"},{"id":"926982-s-3-11","title":"Pregnancy Category","mono":"Tegaserod: B (FDA)<br\/>"},{"id":"926982-s-3-12","title":"Breast Feeding","mono":"Tegaserod: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"926982-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (5% to 12%), Diarrhea (4.2% to 8.8%), Flatulence (6%), Nausea (5% to 8%)<\/li><li><b>Neurologic:<\/b>Headache (15%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cerebrovascular accident, Chest pain, Hypotension, Hypovolemia, Myocardial infarction, Syncope<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (Severe) (0.04%), Ischemic colitis<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><\/ul>"},"6":{"id":"926982-s-6","title":"Drug Name Info","sub":{"0":{"id":"926982-s-6-17","title":"US Trade Names","mono":"Zelnorm<br\/>"},"2":{"id":"926982-s-6-19","title":"Class","mono":"<ul><li>Gastrointestinal Agent<\/li><li>Serotonin Receptor Agonist, 5-HT4<\/li><\/ul>"},"3":{"id":"926982-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"926982-s-7","title":"Mechanism Of Action","mono":"Tegaserod maleate is a 5-HT4 receptor partial agonist and binds with high affinity. Activation of 5-HT4 receptors increases peristaltic reflex, intestinal secretion and inhibits of visceral activity. Stimulation of 5-HT4 also causes the release of neurotransmitters such as calcitonin-gene related peptide from sensory neurons.<br\/>"},"8":{"id":"926982-s-8","title":"Pharmacokinetics","sub":[{"id":"926982-s-8-23","title":"Absorption","mono":"<ul><li>Oral: time to peak concentration, approximately 1 h<\/li><li>Bioavailability: approximately 10%<\/li><li>Effect of food: reduces bioavailability by 40% to 65% and Cmax by 20% to 40%, prolonged Tmax approximately 1 h to 2 h following a meal, but decreases to 0.7 h when taken 30 min prior to meal<\/li><\/ul>"},{"id":"926982-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 368 L +\/-223 L<\/li><li>Protein binding: approximately 98%<\/li><\/ul>"},{"id":"926982-s-8-25","title":"Metabolism","mono":"<ul><li>Presystemic acid hydrolysis followed by oxidation and conjugation, direct glucuronidation<\/li><li>Metabolites: 5-methyoxyindole-3-carboxylic acid glucuronide, isomeric N-glucuronides<\/li><\/ul>"},{"id":"926982-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: approximately two-thirds of the dose unchanged<\/li><li>Renal: one-third of the dose as metabolites<\/li><\/ul>"},{"id":"926982-s-8-27","title":"Elimination Half Life","mono":"11 h +\/- 5 h <br\/>"}]},"9":{"id":"926982-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>administer before meals <br\/>"},"10":{"id":"926982-s-10","title":"Monitoring","mono":"<ul><li>improvement in abdominal pain\/discomfort, bloating, and constipation<\/li><li>signs and symptoms of diarrhea, cramping, abdominal pain, or dizziness<\/li><li>blood pressure, HR; periodic<\/li><\/ul>"},"12":{"id":"926982-s-12","title":"Toxicology","sub":[{"id":"926982-s-12-31","title":"Clinical Effects","mono":"<b>TEGASEROD<\/b><br\/>MARKET WITHDRAWAL: Tegaserod was withdrawn from the market in March 2007 following results of a safety analysis that found a higher risk of heart attack, stroke, and worsening chest pain in patients treated with tegaserod compared to placebo-treated patients. OVERDOSE: Ingestion of up to 20 times the normal therapeutic dose has caused headache, orthostatic hypotension, abdominal pain, diarrhea, nausea, vomiting and flatulence.  ADVERSE EVENTS:  Diarrhea, abdominal pain, flatulence, and headache are the most common adverse effects with tegaserod therapy.  Other adverse effects that may occur less frequently, following therapeutic administration of tegaserod, include dizziness, fatigue, and nausea and vomiting.<br\/>"},{"id":"926982-s-12-32","title":"Treatment","mono":"<b>TEGASEROD <\/b><br\/><ul><li>Decontamination: Serious toxicity is unlikely after acute overdose.  Gastrointestinal  decontamination should only be considered after very large ingestions,  or if significant coingestants are involved.<\/li><li>Support: Treatment is symptomatic and supportive. Serious toxicity is not anticipated.<\/li><li>Monitoring of patient: Monitor fluid and electrolytes in patients that develop severe diarrhea or vomiting. Replace fluids as indicated.<\/li><li>Hemodialysis: Due to its high protein binding and large volume of distribution, it is unlikely hemodialysis or hemoperfusion will be effective.<\/li><\/ul>"},{"id":"926982-s-12-33","title":"Range of Toxicity","mono":"<b>TEGASEROD<\/b><br\/>TOXICITY: No overdose information. In clinical trials, single doses up to 120 mg were well tolerated; one patient developed orthostatic hypotension. Doses of up to 90 to 180 mg\/day over several days resulted in diarrhea (100%), headache (57%), abdominal pain (18%) and nausea and vomiting (7% each). THERAPEUTIC DOSE: Irritable Bowel Syndrome with Constipation OR Chronic Idiopathic Constipation: 6 mg taken twice daily orally before meals; assess need for ongoing therapy in patients.<br\/>"}]},"13":{"id":"926982-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause headache.<\/li><li>Instruct patient to immediately report severe diarrhea and signs\/symptoms of hypotension or syncope.<\/li><li>Advise patient to take drug on an empty stomach, shortly before a meal.<\/li><\/ul>"}}}